Increase transparency, improve communications and reduce administrative burden for all clinical trial stakeholders.


Study start-up timelines are slowing down, causing delays in product launches and ROI.
This white paper summarizes a discussion with Kerry Randall, Vice President and Global Head of Site Activation for IQVIA R&D Solutions, Raphaëlle Gilg, Strategy and Operations Manager for Novartis Pharmaceuticals, Rodrigo Guimarães, Vice President of Global Site Activation for IQVIA R&D Solutions, and Rosemary Shirey, Associate Director of Client Services for IQVIA Technologies.
Increase transparency, improve communications and reduce administrative burden for all clinical trial stakeholders.
Communication, collaboration and transparency between sites and sponsors mean trials start up and close out faster.